Aqr Capital Management LLC Kodiak Sciences Inc. Transaction History

Aqr Capital Management LLC

  • $75.6 Billion
  • Q4 2024

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
BUY
$2.2 - $3.25 $78,181 - $115,495
35,537 New
35,537 $92,000
Q1 2024

May 15, 2024
BUY
$3.01 - $7.45 $69,970 - $173,182
23,246 New
23,246 $122,000
Q3 2023

Nov 14, 2023
BUY
$1.8 - $7.49 $81,212 - $337,933
45,118 New
45,118 $81,000
Q1 2023

May 15, 2023
SELL
$4.81 - $8.88 $182,020 - $336,036
-37,842 Reduced 24.07%
119,360 $740,000
Q4 2022

Feb 14, 2023
BUY
$6.52 - $8.05 $625,437 - $772,204
95,926 Added 156.55%
157,202 $1.13 Million
Q3 2022

Nov 14, 2022
BUY
$7.57 - $12.5 $295,653 - $488,200
39,056 Added 175.77%
61,276 $474,000
Q2 2022

Aug 15, 2022
SELL
$5.04 - $9.48 $81,602 - $153,490
-16,191 Reduced 42.15%
22,220 $170,000
Q1 2022

May 16, 2022
BUY
$7.09 - $89.45 $272,333 - $3.44 Million
38,411 New
38,411 $297,000
Q2 2021

Aug 16, 2021
SELL
$77.2 - $126.54 $502,880 - $824,281
-6,514 Closed
0 $0
Q1 2021

May 17, 2021
BUY
$110.45 - $164.47 $233,712 - $348,018
2,116 Added 48.11%
6,514 $739,000
Q4 2020

Feb 16, 2021
SELL
$60.78 - $154.03 $456,944 - $1.16 Million
-7,518 Reduced 63.09%
4,398 $646,000
Q3 2020

Nov 16, 2020
BUY
$45.05 - $59.27 $187,317 - $246,444
4,158 Added 53.6%
11,916 $706,000
Q2 2020

Aug 17, 2020
BUY
$42.74 - $66.25 $331,576 - $513,967
7,758 New
7,758 $420,000

Others Institutions Holding KOD

# of Institutions
110
Shares Held
40.9M
Call Options Held
13.8K
Put Options Held
5.8K
View Full List

About Kodiak Sciences Inc.

KOD Quotes by TradingView
  • Ticker KOD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,040,200
  • Market Cap $274M
  • Description
  • Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...
More about KOD
Track This Portfolio

Track Aqr Capital Management LLC Portfolio

Follow Aqr Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Aqr Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Aqr Capital Management LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email